EUCTR2007-000123-18-GB进行中（未招募）不适用
A randomised, controlled, parallel, open-labelled, multinational, trial comparing the efficacy and safety of step-wise addition of insulin aspart according to the largest meals (Basic Basal Plus regimen) or the largest prandial increments (Advanced Basal Plus regimen) in combination with once daily insulin detemir and OAD treatment, in subjects with type 2 diabetes
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 512
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Signed informed consent obtained before any trial-related activities (Trial related activities are any procedure that would not have been performed during the normal management of the subject)
- •2.Type 2 diabetes mellitus = 6 months (at visit 2)
- •3.Age = 18 years (at visit 1)
- •4.HbA1c = 7.5% and < 10.0% (at Visit 1)
- •5.BMI < 40.0 kg/m2
- •6.Basal insulin treatment (NPH once or twice daily, insulin glargine once daily or IDet once daily) for at least 3 months (at Visit 2)
- •7.Treatment with 1-3 OADs
- •a.Metformin = 1500 mg daily or highest tolerable dose
- •b.± SU = 50% of maximum dose (in accordance with local labelling)
- •c.± Pioglitazone or Rosiglitazone in accordance with local labelling
- •8.Able and willing to perform SMPG testing as per protocol
- •9.Able and willing to eat 3 main meals each day during the trial
- •10.Able and willing to adhere to the therapeutic regimens
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Known or suspected allergy to trial product(s) or related products
- •2.Previous participation in any trial for the last 3 months
- •3.Previous participation in this trial defined as past inclusion at visit 2
- •4.Women of childbearing potential who are pregnant, breast-feeding or intend to become pregnant within the next 50 weeks or are not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practice).
- •UK: Adequate contraceptive measures are defined as sterilisation, intra-uterine device, oral contraceptives or consistent use of barrier methods
- •5.Use of more than 1 U/kg of basal insulin daily (at Visit 1)
- •6.Treatment with a-glucosidase inhibitors (at Visit 1)
- •7.Treatment with GLP-1 mimetics or DPP-IV inhibitors (at Visit 1)
- •8.Active proliferative retinopathy or maculopathy requiring treatment within 6 mnths prior to screening
- •9.Cardiac disease defined as NYHA class III or IV, unstable angina and/or myocardial infarction within 6 months prior to screening
- •10.Uncontrolled hypertension (treated or untreated) as judged by the Investigator
- •11.Any disease or condition (such as renal, hepatic or cardiac) that according to the judgement of the Investigator makes the subject unsuitable for participation in the trial
- •12.Recurrent (> 2 episodes) hypoglycaemia with PG < 3.1 mmol/L (55.8 mg/dL) within the last month or hypoglycaemic unawareness as judged by the investigator
- •13.Use of concomitant medication which may alter glucose metabolism including but not limited to: systemic (or inhaled) glucocorticoids or non-selective beta-blockers
- •14.Substance abuse including abuse of anabolic steroids
- •15.Mental incapacity or language barrier precluding adequate understanding and/or cooperation
- •16.Any condition that the investigator and/or Sponsor consider a potential obstacle to trial participation and/or data analysis
- •17.Treatment with other insulin than those described in inclusion criteria no. 6
研究者
相似试验
进行中（未招募）
不适用
A randomised, controlled, parallel, open-labelled, multinational, trial comparing the efficacy and safety of step-wise addition of insulin aspart according to the largest meals (Basic Basal Plus regimen) or the largest prandial increments (Advanced Basal Plus regimen) in combination with once daily insulin detemir and OAD treatment, in subjects with type 2 diabetesEUCTR2007-000123-18-SEovo Nordisk A/S512
进行中（未招募）
1 期
A randomised, controlled, parallel, open-labelled, multinational, trial comparing the efficacy and safety of step-wise addition of insulin aspart (NovoRapid®) according to the largest meals (Basic Basal Plus regimen) or the largest prandial increments (Advanced Basal Plus regimen) in combination with once daily insulin detemir (Levemir®) and OAD treatment, in subjects with type 2 diabetestype 2 diabetesMedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2007-000123-18-FRovo Nordisk A/S
进行中（未招募）
不适用
A randomised, controlled, parallel, open-labelled, multinational, trial comparing the efficacy and safety of step-wise addition of insulin aspart according to the largest meals (Basic Basal Plus regimen) or the largest prandial increments (Advanced Basal Plus regimen) in combination with once daily insulin detemir and OAD treatment, in subjects with type 2 diabetestype 2 diabetesMedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2007-000123-18-DKovo Nordisk A/S512
进行中（未招募）
不适用
A randomised, controlled, parallel, open-labelled, multinational, trial comparing the efficacy and safety of step-wise addition of insulin aspart according to the largest meals (Basic Basal Plus regimen) or the largest prandial increments (Advanced Basal Plus regimen) in combination with once daily insulin detemir and OAD treatment, in subjects with type 2 diabetestype 2 diabetesMedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2007-000123-18-FIovo Nordisk A/S512
进行中（未招募）
不适用
A randomised, controlled, parallel, open-labelled, multinational, trial comparing the efficacy and safety of step-wise addition of insulin aspart according to the largest meals (Basic Basal Plus regimen) or the largest prandial increments (Advanced Basal Plus regimen) in combination with once daily insulin detemir and OAD treatment, in subjects with type 2 diabetesType 2 diabetesMedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2007-000123-18-NLovo Nordisk A/S512